Patents by Inventor Michel Perez

Michel Perez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10858423
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 8, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Alexandra Jouhanneaud, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert, Jean-François Haeuw, Ian Rilatt, Michel Perez, Marie Lamothe
  • Publication number: 20200270352
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT, Marie LAMOTHE
  • Patent number: 10633448
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 28, 2020
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Thierry Champion, Alain Robert, Marie Lamothe
  • Publication number: 20200010414
    Abstract: The present invention concerns a compound of following formula (1): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one N or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or C more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
    Type: Application
    Filed: May 30, 2019
    Publication date: January 9, 2020
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
  • Patent number: 10519125
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: December 31, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
  • Patent number: 10454813
    Abstract: A method and a system are provided implementing a mechanism for relaying by all the nodes, on all the networks and sub-networks connected and defined by the routing directive: as soon as a number of cells “n” of different index have been received, whatever the sender thereof, making it possible to reconstruct the message and until, on each of the sub-networks, a predefined number of cells of different index has been sent or received. The relaying comprises decoding the message received and recoding it by a sequence of the unique fountain code on each sending of the same message whatever the relay node.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 22, 2019
    Assignee: THALES
    Inventors: Guy Bouyssounouse, Frédéric Perez, Michel Delattre
  • Publication number: 20190269788
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 16, 2019
    Publication date: September 5, 2019
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
  • Publication number: 20190202901
    Abstract: The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention relates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.
    Type: Application
    Filed: October 26, 2016
    Publication date: July 4, 2019
    Inventors: Alexandra JOUHANNEAUD, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Thierry CHAMPION, Robert ALAIN, Jean-François HAEUW, Ian RILATT, Michel PEREZ
  • Patent number: 10314921
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 11, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
  • Patent number: 10213882
    Abstract: A method for repairing a fan casing in which the inner surface is damaged, includes attaching a reinforcement element to the fan casing, the reinforcement element being attached to the outer surface of the fan casing opposite the damage.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 26, 2019
    Assignee: SAFRAN AIRCRAFT ENGINES
    Inventors: Antoine Patrice Marie Desreumaux, Patrick Jean-Louis Reghezza, Sébastien Marc Jean-Michel Perez
  • Publication number: 20180228915
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 16, 2018
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW
  • Patent number: 10047064
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: August 14, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
  • Publication number: 20180222858
    Abstract: The present invention concerns a compound of following formula (I): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
    Type: Application
    Filed: September 19, 2017
    Publication date: August 9, 2018
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Michel PEREZ, Ian RILATT, Marie LAMOTHE
  • Publication number: 20180086729
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 29, 2018
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
  • Publication number: 20170348808
    Abstract: A method for repairing a fan casing in which the inner surface is damaged, includes attaching a reinforcement element to the fan casing, the reinforcement element being attached to the outer surface of the fan casing opposite the damage.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 7, 2017
    Inventors: Antoine Patrice Marie DESREUMAUX, Patrick Jean-Louis REGHEZZA, Sébastien Marc Jean-Michel PEREZ
  • Patent number: 9669106
    Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 6, 2017
    Assignee: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
  • Publication number: 20170137400
    Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
    Type: Application
    Filed: July 6, 2015
    Publication date: May 18, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric MARION, El Bachir KALOUN, Frédéric LIEBY-MULLER, Michel PEREZ, Jean-Philippe ANNEREAU, Laurent CREANCIER
  • Publication number: 20170112943
    Abstract: The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.
    Type: Application
    Filed: October 26, 2015
    Publication date: April 27, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud, Michel Perez
  • Publication number: 20170043031
    Abstract: The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Mathieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW, Thierry CHAMPION, Alain ROBERT
  • Publication number: 20170043032
    Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
    Type: Application
    Filed: April 27, 2015
    Publication date: February 16, 2017
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-Francois HAEUW